Loading
Endoplasmic Reticulum Stress and Disease · Journal article
mBio · August 10, 2026
Raises a question worth testing. It does not answer one.
This is a mechanistic discovery study coupling C. elegans infection screening with mammalian cell-based validation to identify SKI-II as a candidate immunomodulator that activates antioxidant pathways in macrophages. The work demonstrates target engagement (VCP binding, Nrf2 activation) and signaling effects in vitro but does not report efficacy in whole-animal infection models or clinical data, and thus remains at the hypothesis-generation stage.
Cross-species mechanistic screening study: C. elegans liquid-based infection screen coupled with mammalian cell validation. C. elegans innate immunity reporter strains and mouse RAW264.7 macrophage cell line.. Intervention: SKI-II (small-molecule immunomodulator).
SKI-II identified as host-protective compound activating C. elegans SKN-1/Nrf2 oxidative-stress pathway in six innate immunity reporter strains SKI-II binds to VCP ATPase pocket and activates PERK-dependent Nrf2 signaling in mouse RAW264.7 macrophages SKI-II treatment reduces pathogenic ROS levels and promotes M1 macrophage polarization and mitochondrial metabolic shift
No toxicity, pharmacokinetics, or pharmacodynamic dose-response data provided
This work identifies a potential therapeutic target (VCP) and candidate small molecule (SKI-II) for host-directed immunity, but in vivo efficacy in mammals and human relevance remain to be demonstrated. Clinicians should await validation in animal infection models and toxicology data before considering this for further development.
Early-stage mechanistic discovery in model organisms and cultured cells identifying a candidate compound and signaling pathway, without in vivo efficacy data or clinical translation.
As stated by the source record.
This work identifies a potential therapeutic target (VCP) and candidate small molecule (SKI-II) for host-directed immunity, but in vivo efficacy in mammals and human relevance remain to be demonstrated. Clinicians should await validation in animal infection models and toxicology data before considering this for further development.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Antibiotic resistance threatens the effectiveness of conventional antimicrobial agents, underscoring the need for host-directed therapies that enhance immune defense. Here, we present a cross-species discovery pipeline that couples a Caenorhabditis elegans–Staphylococcus aureus liquid-based infection screen with mammalian mechanistic validation to identify small-molecule immunomodulators. Using six C. elegans innate immunity reporter strains, we identified a known small molecule, SKI-II, as a previously unrecognized host-protective compound that activates the C. elegans SKN-1/Nrf2 oxidative-stress pathway. In mouse RAW264.7 macrophages, SKI-II binds to the ATPase pocket of VCP (Valosin-Containing Protein), activating the PERK-dependent (Protein kinase R [PKR]-like Endoplasmic Reticulum Kinase) Nrf2 signaling regulation axis that reduces the levels of pathogenic ROS (reactive oxygen species). SKI-II treatment also promotes macrophage M1 polarization and a mitochondrial metabolic shift. This work identifies VCP as a druggable node for host-directed immunomodulation and highlights SKI-II as a prototype small molecule that boosts host tolerance to infection, thereby validating our C. elegans -based screening platform for discovering immunomodulators active in mammalian systems. IMPORTANCE Enhancing host immunity is a promising strategy to combat S. aureus infection, particularly multidrug-resistant strains. In this study, we applied a C. elegans liquid-based infection screening model to identify the immunomodulatory compound SKI-II. We demonstrate that SKI-II protects against S. aureus infection in both nematodes and mouse macrophages by regulating host oxidative stress pathways rather than directly targeting the pathogen. We reveal a regulatory circuit in which VCP functions as a central node controlling cellular ROS responses and activating the downstream PERK-dependent Nrf2 antioxidant signaling pathway. These findings advance our understanding of host cellular responses to bacterial infection and highlight VCP as a druggable target for host-directed therapeutic strategies against infectious diseases.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.